NasdaqCM:ONDS
NasdaqCM:ONDSCommunications

Ondas Holdings (ONDS): Revisiting Valuation After a Powerful Momentum-Driven Share Price Surge

Ondas Holdings (ONDS) has quietly turned into a serious momentum story, with the stock up sharply this year as investors warm to its mix of industrial wireless networks and autonomous drone technology. See our latest analysis for Ondas Holdings. That enthusiasm is showing up clearly in the numbers, with a 7 day share price return of 23.9 percent feeding into a powerful year to date share price gain of 247.2 percent and a 1 year total shareholder return of 352.0 percent. This suggests...
TSX:AG
TSX:AGMetals and Mining

How Investors May Respond To First Majestic Silver (TSX:AG) Leadership Changes And Santa Elena Drill Results

First Majestic Silver Corp. recently announced that Mani Alkhafaji will become President & Chief Corporate Development Officer from January 1, 2026, while Keith Neumeyer will continue as Chief Executive Officer, alongside releasing encouraging exploration and mine-planning updates at its Santa Elena Silver/Gold Mine in Mexico. The combination of materially expanded mineralization at the Santo Niño and Navidad targets, excellent third-party metallurgical recoveries above 95%, and...
NasdaqGM:TVTX
NasdaqGM:TVTXBiotechs

Travere Therapeutics (TVTX) Is Up 18.9% After FDA Moves Ease Path For FILSPARI’s FSGS Expansion

In December 2025, Travere Therapeutics reported a series of favorable FDA updates for FILSPARI, including the cancellation of an advisory committee review, easing of REMS requirements, and growing regulatory acceptance of proteinuria reduction as a key endpoint ahead of a January 2026 decision on expanding its use to focal segmental glomerulosclerosis (FSGS). These regulatory developments highlight how Travere’s lead kidney drug could potentially broaden its reach in an area with limited...
NYSE:OWL
NYSE:OWLCapital Markets

Blue Owl Capital (OWL): Assessing Valuation After a Recent Share Price Rebound

Blue Owl Capital (OWL) has been grinding through a rough stretch, but its recent bounce over the past month has some investors asking whether the selloff has finally gone too far. See our latest analysis for Blue Owl Capital. At around $15.46, Blue Owl’s recent 1 month share price return of just over 9 percent comes after a much tougher stretch, with year to date share price performance still deeply negative even as its 3 year total shareholder return remains strongly positive. This suggests...
NYSE:MSI
NYSE:MSICommunications

Silvus Acquisition and Public Safety Tech Push Could Be A Game Changer For Motorola Solutions (MSI)

Earlier this month, Morgan Stanley upgraded Motorola Solutions to Overweight, pointing to improved growth prospects as the company integrates its US$4.40 billion Silvus Technologies acquisition and continues investing in advanced public safety technology. The completed Silvus deal deepens Motorola Solutions’ capabilities in secure, wireless communications for government and defense customers, potentially reinforcing its role in mission‑critical public safety infrastructure globally. Now...
NasdaqGS:PAYX
NasdaqGS:PAYXProfessional Services

Should Paychex’s Upgraded Outlook and AI Push Require Action From Paychex (PAYX) Investors?

In the past week, Paychex reported fiscal second-quarter 2025 results showing revenue rising to US$1,557.6 million while net income and earnings per share eased modestly year-on-year, and it also completed a US$390.62 million buyback of 2,928,855 shares under its January 2024 authorization. Management raised its adjusted earnings outlook for fiscal 2026, pointing to stronger-than-expected contributions from the Paycor acquisition and early benefits from new AI-driven HR and compliance tools,...
NYSE:RBRK
NYSE:RBRKSoftware

Rubrik (RBRK): Reassessing Valuation After Strong Q3 Beat, Raised 2026 Guidance and Growing AI-Driven Demand

Rubrik (RBRK) has been in the spotlight after its stronger than expected Q3 results. Subscription ARR is jumping, margins are improving, and management has lifted 2026 guidance, all while investor buzz keeps building. See our latest analysis for Rubrik. That upbeat Q3 update seems to be feeding into the story, with Rubrik’s 30 day share price return of 16.93 percent lifting the stock to 78.80 dollars. Year to date momentum looks solid, even though the one year total shareholder return sits at...
NasdaqGS:AKAM
NasdaqGS:AKAMIT

Akamai (AKAM): Valuation Check After New ISV Catalyst Program and Strategic Visa Partnership

Akamai Technologies (AKAM) just rolled out its ISV Catalyst partner program and a separate strategic tie up with Visa, moves that quietly tighten its grip on AI ready cloud infrastructure and secure, agent driven commerce. See our latest analysis for Akamai Technologies. These moves land as Akamai’s 90 day share price return of 17.83 percent contrasts with a negative year to date share price return of 6.92 percent and a one year total shareholder return of 8.35 percent in the red, suggesting...
NYSE:ABBV
NYSE:ABBVBiotechs

Has AbbVie’s 2025 Surge Already Priced In Its Expanding Immunology and Oncology Pipeline?

If you are wondering whether AbbVie is still attractive after its massive run, or if the value story has already played out, this breakdown outlines the key factors that can help you assess whether the current price makes sense. The stock has climbed 28.1% year to date and 32.2% over the last year, with a 58.2% return over three years and 165.4% over five. This performance naturally raises questions about how much upside may remain from here. Recent headlines have focused on AbbVie's...
NasdaqGS:ONC
NasdaqGS:ONCBiotechs

Is It Too Late To Consider BeOne Medicines After Its 2025 Oncology Pipeline Surge?

Wondering if BeOne Medicines is still a smart buy after its big run up, or if the easy money has already been made? Here is a closer look at what the current share price implies about its long term potential. The stock has been volatile lately, slipping 6.3% over the last month but still up 1.9% in the past week, and 69.4% year to date and 71.6% over the past year. This suggests the market is rapidly updating its view of the company. Recent headlines around BeOne Medicines have centered on...
NasdaqGS:SBUX
NasdaqGS:SBUXHospitality

Is Starbucks Share Price Justified After Recent Slide And Premium Valuation Metrics?

If you are wondering whether Starbucks at around $84 a share is a bargain or a value trap right now, you are not alone. This makes it a good moment to unpack what the market is really pricing in. Over the past year the stock is down about 3.4%, with a softer 8.2% slide year to date, but a modest 1.5% gain over the last month hints that sentiment might be stabilizing as investors reassess its long term growth story. Recently, markets have been weighing Starbucks strategic push into new store...
NYSE:BABA
NYSE:BABAMultiline Retail

Assessing Alibaba Group Holding (NYSE:BABA) Valuation as AI Investments and Cloud Expansion Accelerate

Alibaba Group Holding (NYSE:BABA) is back in the spotlight after a flurry of AI focused moves, from massive accelerator orders with global chipmakers to new multilingual models and agent platforms rolling out across its ecosystem. See our latest analysis for Alibaba Group Holding. All of this AI momentum is landing against a backdrop where Alibaba’s share price has pulled back, with a 1 month share price return of negative 6.6% and a 3 month share price return of negative 14.5%. At the same...
NYSE:ASA
NYSE:ASACapital Markets

Assessing ASA Gold and Precious Metals (NYSE:ASA) Valuation After Strong Earnings Highlight and Market Rally Interest

ASA Gold and Precious Metals (ASA) has just been spotlighted as a rare opportunity in the metals and mining space, after its strong earnings and revenue growth stood out during the latest US market rally. See our latest analysis for ASA Gold and Precious Metals. That attention has come on the back of powerful price action, with a roughly 27 percent 30 day share price return and a 192 percent year to date share price return. The 1 year total shareholder return above 200 percent signals that...
NYSE:ARE
NYSE:AREHealth Care REITs

Alexandria Real Estate Equities (ARE) Valuation After Lawsuits, Guidance Cut, Dividend Reduction and Negative S&P Outlook

Alexandria Real Estate Equities (ARE) is back in the spotlight as multiple class action lawsuits, a sharp guidance reset, and an S&P outlook cut converge, forcing investors to reassess this beaten down life science REIT. See our latest analysis for Alexandria Real Estate Equities. All of this legal and ratings pressure has played out in the numbers, with Alexandria’s share price now at $48.76 after a roughly 50 percent year to date share price decline and an even steeper multi year total...
NYSE:SE
NYSE:SEMultiline Retail

Does Sea’s Profitability Pivot Justify the Recent 20.4% Rally in 2025?

Wondering if Sea at around $126 a share is still a smart buy or if the big gains are already behind it? This breakdown will help you decide whether the current price matches the company’s long term potential. The stock is up 6.1% over the last week and 20.4% year to date, even after a choppier patch that left it down 7.4% over the last month and still 35.8% lower over 5 years. Recent headlines have focused on Sea sharpening its focus on profitability and capital discipline, including pulling...
NasdaqGS:RGEN
NasdaqGS:RGENLife Sciences

Is Repligen (RGEN) Quietly Recasting Its Gene Therapy Moat With New HiPer Viral Vector Resins?

In December 2025, Repligen Corporation launched three new high-performance chromatography resins, AVIPure® HiPer™ AAV9, AVIPure® HiPer™ AAV8, and HiPer™ QA, built on Tantti™ DuloCore™ technology to support advanced bioprocessing and gene therapy applications. By extending its proteins and viral-vector-focused resin portfolio ahead of broader chromatography launches expected in 2026, Repligen is positioning itself as a more integral tools provider for next-generation gene therapy...
NYSE:HD
NYSE:HDSpecialty Retail

Does Home Depot’s Cautious 2026 Outlook And Security Issue Change The Bull Case For HD?

Earlier this week, Home Depot reaffirmed its fiscal 2025 guidance and issued a cautious 2026 outlook, pointing to ongoing housing market softness, restrained discretionary project spending, and a modest sales and earnings growth profile while it prioritizes Pro customer relationships and integrates recent acquisitions. The update also flagged a recent security issue involving leaked internal credentials, adding an operational risk angle to an already macro-sensitive business story built...
NasdaqGS:NTSK
NasdaqGS:NTSKSoftware

Netskope (NTSK): Reassessing Valuation After Strong First Post‑IPO Earnings and Upbeat Growth Guidance

Netskope (NTSK) just cleared its first post IPO hurdle with earnings that beat expectations, and the market is now trying to square that growth story with widening losses. See our latest analysis for Netskope. Even with that upbeat debut, the 90 day share price return of negative 18.5 percent and year to date share price return of negative 17.7 percent show momentum has cooled lately. This suggests investors are still recalibrating growth potential against heavier reported losses. If Netskope...